Calcilytix Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Calcilytix Therapeutics's estimated annual revenue is currently $2.8M per year.
- Calcilytix Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Calcilytix Therapeutics has 18 Employees.
- Calcilytix Therapeutics grew their employee count by 13% last year.
Calcilytix Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director | Reveal Email/Phone |
2 | Director - Drug Substance Development and Manfacturing (Calcilytix and MLBio) | Reveal Email/Phone |
3 | Director, Analytical Development | Reveal Email/Phone |
4 | Senior Clinical Trial Manager | Reveal Email/Phone |
Calcilytix Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Calcilytix Therapeutics?
Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, hypothesized to restore normal serum calcium and lower urine calcium.
keywords:N/A
N/A
Total Funding
18
Number of Employees
$2.8M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.4M | 18 | 6% | $38.3M |
#2 | $0.6M | 18 | -5% | $88.5M |
#3 | $1.7M | 18 | 0% | N/A |
#4 | $1.4M | 18 | -44% | $37.8M |
#5 | $1.6M | 18 | -10% | N/A |